Dwight H Owen, MD, MS
Academic Title: Associate Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am a medical oncologist who specializes in treating patients with thoracic malignancies, including lung cancer, mesothelioma and thymic cancers. I completed my residency in internal medicine at Downstate Medical Center in Brooklyn, NY, and my chief residency at Memorial Sloan Kettering Cancer Center. I came to The Ohio State University for my fellowship in hematology and medical oncology, which I completed in 2017, serving as chief fellow for the 2016–2017 academic year. While in that position, I expanded upon our systems-based education curriculum and led the development of a Quality Improvement Program to optimize procedure training for our new fellows. As a member of the Translational Therapeutics Program at the OSUCCC – James, my research interests include the use of immunotherapy in patients with thoracic cancers and developing ways to better identify patients who are likely to benefit most from these treatments while minimizing toxicities. Under the mentorship of Dr. David Carbone and Dr. Gregory Otterson, I have written several early phase trials for patients with thoracic malignancies, including a multi-center phase II trial of immunotherapy in early stage non-small cell lung cancer. My research has been published in the Journal of Clinical Oncology, Journal of Thoracic Disease and Journal of Oncology Practice, among others, and I am honored to have been selected as a recipient of the American Society of Clinical Oncology Conquer Cancer Foundation’s Young Investigator Award. I feel very fortunate to be at The James and to be surrounded by passionate team members, clinicians and scientists who are all focused on improving the treatment and care of patients with cancer. Having done my fellowship training here, I have been awed by the impact that The James has had in this community. It’s been extremely rewarding working together to help our patients.
Clinical Expertise
More info for- Lung Cancers
- Thoracic Diseases
- Immunotherapy
- Mesothelioma
Where I See Patients
More info forEducation & Training
More info forResidency - Internal Medicine
- Memorial Sloan-Kettering Cancer Center
1275 York Ave, New York, NY
Fellowship - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Internship - Internal Medicine
- SUNY Downstate Medical Center
450 Clarkson Ave, Brooklyn, NY
Residency - Internal Medicine
- SUNY Downstate Medical Center
450 Clarkson Ave, Brooklyn, NY
Graduate
- The Ohio State University Graduate School
230 N Oval Mall, Columbus, OH
Medical School
- Trinity College Dublin School of Medicine
Level 1, Trinity Biomedical Sciences Institute, Dublin
- Memorial Sloan-Kettering Cancer Center
Academic Office & Contact Information
More info forAcademic Office:
Lincoln Tower 1335
1800 Cannon Dr
Columbus, Ohio 43210Phone:
614-685-2039Email:
owen.257@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forNovember 4, 2024Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non-Small Cell Lung Cancer.
JAMA Netw Open
October 9, 2024CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV
Nature
October 2, 2024Role for Artificial Intelligence in the Detection of Immune-Related Adverse Events.
Elsaid MI, Meara AS, Owen DH
J Clin Oncol
September 12, 2024Improved survival for patients with lung cancer treated with perioperative immunotherapy.
Presley CJ, Owen DH
Lancet
June 17, 2024Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis.
Moodabagil M, Easterling R, Peng J, Abu-Sbeih H, Meara A, Donnelly E, Owen DH, Ho K
Oncologist
June 3, 2024Safety and Efficacy Outcomes of Early Cessation of Anti-PD1 Therapy in Patients 80 Years or Older: A Retrospective Cohort Study.
Fletcher K, Cortellini A, Ganta T, Kankaria R, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Presley CJ, Owen DH, Abou Alaiwi S, Nassar AH, Lamberti G, Perrone F, Buti S, Giusti R, Filetti M, Vanella V, Mallardo D, Sussman TA, Galetta D, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Nebhan C, Berg S, Choueiri TK, Marron TU, Wang Y, Naqash AR, Johnson DB
Cancer Lett
May 30, 2024Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1.
Owen DH, Ismaila N, Freeman-Daily J, Roof L, Singh N, Velazquez AI, Leighl NB
J Clin Oncol
May 1, 2024Non-Small Cell Lung Cancer, Version 4.2024.
Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hang L
J Natl Compr Canc Netw
April 20, 2024Sarcoid-Like Reactions to Immune Checkpoint Inhibitors: Incidence, Treatment Course, and Impact on Cancer Progression and Survival.
Smith H, Easterling R, Ma J, Moodabagil M, Meara A, Owen DH, Crouser E, Singha A, Ho K
Respir Med
April 8, 2024Therapy for Stage IV Non-Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights.
Owen DH, Jaiyesimi IA, Leighl NB, Ismaila N, Florez N, Puri S, Schenk EL, Schneider BJ, Patel JD
JCO Oncol Pract
April 5, 2024HSR24-160: Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus: Patient Characteristics, Clinical Outcomes, and Survival Implications of Autoantibodies.
Sharp J, Pasadyn C, Zhao S, Wei L, Presley C, Owen D, Wyne K, Meara A
J Natl Compr Canc Netw
April 5, 2024CLO24-061: Overall Survival (OS) Impact for NSCLC Patients With irAE and Non-irAE Hospital Admissions During First-Line Pembrolizumab Treatment.
Khorasanchi A, Zhao S, Wei L, Li M, Ho K, Abu-Sbeih H, Goodyear E, Secor A, Shields P, He K, Kaufman J, Memmott R, Alahmadi A, Carbone D, Otterson G, Meara A, Presley C, Owen D
J Natl Compr Canc Netw
April 5, 2024CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non-Small Cell Lung Cancer.
Sharp J, Jones D, Rotow J, Fidias P, Bertino E, Owen D
J Natl Compr Canc Netw
March 13, 2024Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.
Sharp JA, Jones D, Rotow JK, Fidias PM, Bertino E, Owen DH
J Natl Compr Canc Netw
March 13, 2024Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine Tumor Fraction in Advanced Cancers.
Rickles-Young M, Tinoco G, Tsuji J, Pollock S, Haynam M, Lefebvre H, Glover K, Owen DH, Collier KA, Ha G, Adalsteinsson VA, Cibulskis C, Lennon NJ, Stover DG
J Mol Diagn
February 28, 2024Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD
J Clin Oncol
February 28, 2024Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD
J Clin Oncol
February 20, 2024A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
Williams TM, Miller E, Welliver M, Brownstein J, Otterson G, Owen D, Haglund K, Shields P, Bertino E, Presley C, He K, Naduparambil J, Walston S, Pan J, Yang X, Knopp M, Essan JK, McElroy J, Mo X, McElroy S, Carbone D, Bazan J
Int J Radiat Oncol Biol Phys
January 24, 2024Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Manana AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Espinar JB, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB
J Thorac Oncol
January 23, 2024Novel endoscopic scoring system for immune mediated colitis: A Multicenter Retrospective Study of 674 Patients.
Wang Y, Abu-Sbeih H, Tang T, Shatila M, Faleck D, Harris J, Dougan M, Olsson-Brown A, Johnson DB, Shi C, Grivas P, Diamantopoulos L, Owen DH, Cassol C, Arnold CA, Warner DE, Alva A, Powell N, Ibraheim H, De Toni EN, Philipp AB, Philpott J, Sleiman J, Lythgoe M, Daniels E, Sandhu S, Weppler AM, Buckle A, Pinato DJ, Thomas A, Qiao W
Gastrointest Endosc
January 1, 2024Immune-related adverse event in the emergency department: methodology of the immune-related emergency disposition index (IrEDi).
Reyes-Gibby CC, Caterino JM, Coyne CJ, Kyriacou DN, Qdaisat A, McQuade J, Owen DH, Bischof JJ, Shete S, Yeung SJ
Emerg Cancer Care
December 23, 2023Decoupling FcRn and Tumor Contributions to Elevated Immune Checkpoint Inhibitor Clearance in Cancer Cachexia.
Vu TT, Kim K, Manna M, Thomas J, Remaily B, Montgomery EJ, Costa T, Granchie L, Xie Z, Guo Y, Chen M, Castillo AMM, Kulp SK, Mo X, Nimmagadda S, Gregorevic P, Owen DH, Ganesan LP, Mace TA, Coss CC, Phelps MA
Pharmacol Res
November 3, 2023Antibody drug clearance: an underexplored marker of outcomes with checkpoint inhibitors.
Guo Y, Remaily BC, Thomas J, Kim K, Kulp SK, Mace TA, Ganesan LP, Owen DH, Coss CC, Phelps MA
Clin Cancer Res
November 1, 2023Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
Wong A, Riley M, Zhao S, Zimmer J, Viveiros M, Wang JG, Esguerra V, Li M, Lopez G, Kendra K, Carbone DP, He K, Alahmadi A, Kaufman J, Memmott RM, Shields PG, Brownstein J, Haglund K, Welliver M, Otterson GA, Presley CJ, Wei L, Owen DH, Ho K
J Natl Compr Canc Netw
October 10, 2023Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP, LCMC study investigators
Nat Med
October 1, 2023Upfront Osimertinib Alone vs. Osimertinib and Radiotherapy for the Treatment of EGFR-Positive NSCLC Brain Metastases: A Multi-Institutional Series.
Dohm AE, Upadhyay R, Tang JD, Oliver DE, Perez BA, Rosenberg SA, Yu HHM, Palmer JD, Beyer S, Owen D, Ahmed KA
Int J Radiat Oncol Biol Phys
May 19, 2023Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.
Mital R, Otto TS, Savu A, Baumrin E, Cardones AR, Carlesimo M, Caro G, Freites-Martinez A, Hirner JP, Markova A, McLellan BN, Rossi A, Sauder MB, Seminario-Vidal L, Sibaud V, Owen DH, Dulmage BO, Chen ST, Kaffenberger BH
Int J Dermatol
May 17, 2023Improving combination therapies: Targeting A2B adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.
Evans JV, Suman S, Goruganthu MUL, Tchekneva EE, Guan S, Arasada RR, Antonucci A, Piao L, Ilgisonis I, Bobko AA, Driesschaert B, Uzhachenko RV, Hoyd R, Samouilov A, Amann J, Wu R, Wei L, Pallerla A, Ryzhov SV, Feoktistov I, Park KP, Kikuchi T, Castro J, Ivanova AV, Kanagasabai T, Owen DH, Spakowicz DJ, Zweier JL, Carbone DP, Novitskiy SV, Khramtsov VV, Shanker A, Dikov MM
J Natl Cancer Inst
May 16, 2023Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
El Zarif T, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR
J Clin Oncol
April 21, 2023Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer.
Johns AC, Yang M, Wei L, Grogan M, Spakowicz D, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Rosko AE, Andersen BL, Carbone DP, Owen DH, Presley CJ
Oncologist
April 17, 2023Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.
Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F
Cancer Discov
April 6, 2023Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1.
Singh N, Jaiyesimi IA, Ismaila N, Leighl NB, Mamdani H, Phillips T, Owen DH
J Clin Oncol
April 6, 2023Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1.
Singh N, Jaiyesimi IA, Ismaila N, Leighl NB, Mamdani H, Phillips T, Owen DH
J Clin Oncol
January 1, 2023Improvement in Survival for Patients With Lung Cancer in Taiwan: Implications and Call to Action.
Oezkan F, Seweryn M, Shukuya T, Owen DH
J Thorac Oncol
January 1, 2023Generalizability of machine learning methods in detecting adverse drug events from clinical narratives in electronic medical records.
Zitu MM, Zhang S, Owen DH, Chiang C, Li L
Front Pharmacol
December 19, 2022Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2.
Owen DH, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, Jain D, Leighl NB, Mamdani H, Masters G, Moffitt PR, Naidoo J, Phillips T, Riely GJ, Robinson AG, Schenk E, Schneider BJ, Sequist L, Spigel DR, Jaiyesimi IA
J Clin Oncol
December 19, 2022Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2.
Owen DH, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, Jain D, Leighl NB, Mamdani H, Masters G, Moffitt PR, Naidoo J, Phillips T, Riely GJ, Robinson AG, Schenk E, Schneider BJ, Sequist L, Spigel DR, Jaiyesimi IA
J Clin Oncol
September 12, 2022Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP, LCMC study investigators
Nat Med
September 7, 2022Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival.
Miah A, Tinoco G, Zhao S, Wei L, Johns A, Patel S, Li M, Grogan M, Lopez G, Husain M, Hoyd R, Mumtaz K, Meara A, Bertino EM, Kendra K, Spakowicz D, Otterson GA, Presley CJ, Owen DH
J Cancer Res Clin Oncol
September 7, 2022Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors.
Matsui JK, Perlow HK, Raj RK, Nalin AP, Lehrer EJ, Kotecha R, Trifiletti DM, McClelland S, Kendra K, Williams N, Owen DH, Presley CJ, Thomas EM, Beyer SJ, Blakaj DM, Ahluwalia MS, Raval RR, Palmer JD
Biomedicines
September 1, 2022An Informatics Bridge to Improve the Design and Efficiency of Phase I Clinical Trials for Anticancer Drug Combinations.
Wang L, Wei L, Zhang S, Cheng L, Shendre A, Carson W, Chen JL, Owen D, Gregory M, Li L
Cancer Res Commun
July 4, 2022Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer.
Issa M, Tang J, Guo Y, Coss C, Mace TA, Bischof J, Phelps M, Presley CJ, Owen DH
Expert Rev Anticancer Ther
June 25, 2022The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer.
Thomas J, Torok MA, Agrawal K, Pfau T, Vu TT, Lyberger J, Chang H, Castillo AMM, Chen M, Remaily B, Kim K, Xie Z, Dillhoff ME, Kulp SK, Behbehani GK, Cruz-Monserrate Z, Ganesan LP, Owen DH, Phelps MA, Coss CC, Mace TA
Int J Mol Sci
January 8, 2022Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Coss CC, Phelps MA, Owen DH
Clin Lung Cancer
January 1, 2022Association between immune-related adverse event timing and treatment outcomes.
Hsiehchen D, Naqash AR, Espinoza M, Von Itzstein MS, Cortellini A, Ricciuti B, Owen DH, Laharwal M, Toi Y, Burke M, Xie Y, Gerber DE
Oncoimmunology
November 4, 2021Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutilo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Choueiri TK, Johnson DB, Marron TU, Wang Y, Naqash AR
JAMA Oncol
November 1, 2021A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC).
Williams TM, Welliver MX, Brownstein JM, Otterson G, Owen D, Pan J, Haglund KE, Shields PG, Bertino EM, Presley C, He K, Miller ED, Yang X, Knopp M, Essan JK, McElroy S, Carbone DP, Bazan JG
Int J Radiat Oncol Biol Phys
October 7, 2021Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival.
Haddad TC, Zhao S, Li M, Patel SH, Johns A, Grogan M, Lopez G, Miah A, Wei L, Tinoco G, Riesenberg B, Li Z, Meara A, Bertino EM, Kendra K, Otterson G, Presley CJ, Owen DH
Cancer Immunol Immunother
October 1, 2021Acute kidney injury in patients treated with immune checkpoint inhibitors.
Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE, ICPi-AKI Consortium
J Immunother Cancer
August 13, 2021Harmonized Outcome Measures for Use in Non-Small Cell Lung Cancer Patient Registries and Clinical Practice.
Edelman MJ, Raymond DP, Owen DH, Leavy MB, Chansky K, Yennu S, Fernandez FG, Presley CJ, Biswas T, Quinn GP, Schabath MB, Sheffler-Collins S, Chu L, Gliklich RE
J Natl Compr Canc Netw
July 1, 2021Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans.
Castillo AMM, Vu TT, Liva SG, Chen M, Xie Z, Thomas J, Remaily B, Guo Y, Subrayan UL, Costa T, Helms TH, Irby DJ, Kim K, Owen DH, Kulp SK, Mace TA, Phelps MA, Coss CC
JCSM Rapid Commun
April 20, 2021Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Qin A, Zhao S, Miah A, Wei L, Patel S, Johns A, Grogan M, Bertino EM, He K, Shields PG, Kalemkerian GP, Gadgeel SM, Ramnath N, Schneider BJ, Hassan KA, Szerlip N, Chopra Z, Journey S, Waninger J, Spakowicz D, Carbone DP, Presley CJ, Otterson GA, Green MD, Owen DH
J Natl Compr Canc Netw
February 24, 2021Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events.
Nashed A, Zhang S, Chiang CW, Zitu M, Otterson GA, Presley CJ, Kendra K, Patel SH, Johns A, Li M, Grogan M, Lopez G, Owen DH, Li L
Cancer Immunol Immunother
February 21, 2021Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer.
Johns AC, Wei L, Grogan M, Hoyd R, Bridges JFP, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Burkart JT, Rosko AE, Andersen BL, Carbone DP, Owen DH, Spakowicz DJ, Presley CJ
J Geriatr Oncol
December 2, 2020Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG, Janse S, Owen DH, Kiourtsis S, Bertino EM, He K, Carbone DP, Otterson GA
Clin Lung Cancer
December 1, 2020Second cancer incidence in CLL patients receiving BTK inhibitors.
Bond DA, Huang Y, Fisher JL, Ruppert AS, Owen DH, Bertino EM, Rogers KA, Bhat SA, Grever MR, Jaglowski SM, Maddocks KJ, Byrd JC, Woyach JA
Leukemia
November 2, 2020Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells.
Owen DH, Benner B, Pilcher C, Good L, Savardekar H, Norman R, Ghattas C, Shah M, Konda B, Verschraegen CF, Wesolowski R, Behbehani GK, Carson WE, Otterson GA
Clin Lung Cancer
October 29, 2020Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J
JAMA Oncol
September 1, 2020Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy.
Zhou N, Velez MA, Owen D, Lisberg AE
J Natl Compr Canc Netw
July 29, 2020Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Li M, Spakowicz D, Zhao S, Patel SH, Johns A, Grogan M, Miah A, Husain M, He K, Bertino EM, Shields PG, Wei L, Carbone DP, Otterson GA, Presley CJ, Owen DH
Cancer Immunol Immunother
June 18, 2020Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
Kander EM, Shah MH, Zhou Y, Goyal A, Palmer JD, Owen DH, Shilo K, Patel G, Raval RR, Gonzalez J, Nguyen M, Olek E, Kherani J, Rothenberg SM, Konda B
Clin Lung Cancer
June 11, 2020Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.
Iyer RV, Konda B, Fountzilas C, Mukherjee S, Owen D, Attwood K, Wang C, Suffren SA, Hicks K, Wilton J, Bies R, Casucci D, Reidy-Lagunes D, Shah M
Cancer
May 15, 2020The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer.
Jain R, Coss C, Whooley P, Phelps M, Owen DH
Curr Oncol Rep
May 6, 2020Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.
Spakowicz D, Hoyd R, Muniak M, Husain M, Bassett JS, Wang L, Tinoco G, Patel SH, Burkart J, Miah A, Li M, Johns A, Grogan M, Carbone DP, Verschraegen CF, Kendra KL, Otterson GA, Li L, Presley CJ, Owen DH
BMC Cancer
April 28, 2020Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, Sugawara S, Burkart J, Park W, Chiari R, Sugisaka J, Otterson GA, de Lima Lopes G, Walker PR
Cancer Immunol Immunother
April 16, 2020PD-1 and PD-L1 expression in PD-1 Inhibitor-Associated Colitis and Its Mimics.
Cassol CA, Owen D, Kendra K, Braga JR, Frankel WL, Arnold CA
Histopathology
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Owen has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- Chugai Pharma
Patient Comments
Dr Owen always takes time to go over everything
Dr Owen and staff have been wonderful. Dr Owen always takes his time with us. Explains things clearly and makes sure you understand before he leaves. If questions do arise after he's gone the staff always make it point to get us answers before we go. We have full and complete confidence in this group!
I can't say enough about Dr. Owen. He has excellent listening skills and is so empathetic. I also discussed my health with one of his fellows and found him to have the same attributes. I feel so very fortunate to have such wonderful care.
Enjoy seeing Dr Owen and going over results Always better news each visit
Okay
Excellent visit as always
Very Good
Dr Owens is a fantastic doctor. Always listened and allowed me to participate in care decisions
I always knew I would pick OSU if I got cancer and it truly is remarkable. I feel so very fortunate to live so close to a first class treatment's facility. I count my blessings every day!
Dr Owen is very caring and informative
Great visit; as usualDr Owen was very attentive and thorough in answering question
Dr Owens always takes time to answer my questions & concerns
Well prepared for our meeting.
Dr. Owen is great! The wait time was due to the intake coordinators. Dr. Owen still spent plenty of time w/me and I learn a lot.
Great staff of care workers.